-
Bank Ranking
Banks Ratios
Cement Statistics
Cement Ranking
Cement Ratios
Monetary and Economic Statistics
Oil, Gas and Fuel
Macro Economy
Consumer Spending
Inflation
Exports & Imports
Food Prices
Non Food Prices
Construction Materials
Petrochem. Ranking
Petrochem. Ratios
Retail Rankings
Retail Ratios
Grocery Ranking
Grocery Ratios
Top Growth
Dividend History
Jamjoom Pharma revises up 2023 guidance
10/08/2023
Argaam Special
AI Summary
Content Summary:
AI Summary
Content Summary: 
Loading data...
Please note that this news summary has been generated using artificial intelligence. It is recommended to review the original
sources for complete details and to verify the accuracy of the information.
Logo of Jamjoom Pharma
Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) updated its outlook and guidance for 2023.
The pharmaceutical producer revised up its previous guidance for revenues and earnings before interest, taxes, depreciation, and amortization (EBITDA) margins, following the strong growth reported in the first half of 2023.
|
Period |
Actual – H1 2023 |
Previous Guidance |
Updated Guidance |
|
Revenue Growth |
+24% |
15-17% |
17-19% |
|
EBITDA Margin |
33.2% |
30% |
31% |
|
CAPEX |
3.2% |
-- |
4-6% |
The company attributed the 24% rise in revenue to better demand and the price hike applied to some key products in late Q1 2023. Jamjoom Pharma’s manufacturing capacity was ramped up by the end of Q2 2023.
Comments {{getCommentCount()}}
Be the first to comment
{{Comments.indexOf(comment)+1}}
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.
Market Indices
TASI
11,251.81
84.27
0.75 %
Quotes
JAMJOOM PHARMA
131.00
2.10
1.63%
Call Request
Comments Analysis: